# Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma

> **NCT02945319** · — · COMPLETED · sponsor: **International Extranodal Lymphoma Study Group (IELSG)** · enrollment: 373 (actual)

## Conditions studied

- Splenic Marginal Zone Lymphoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02945319
- **Lead sponsor:** International Extranodal Lymphoma Study Group (IELSG)
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 373 (ACTUAL)
- **Last updated:** 2021-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02945319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02945319, "Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02945319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*